Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 1:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: zolpidem tartrate Clear all
Completed Phase 3 Interventional Results available

A Study to Evaluate Next-Dose Transition From Zolpidem to Lemborexant (LEM) for the Treatment of Insomnia

NCT04009577
View directory record Official record
Conditions
Insomnia
Interventions
LEM 5 mg, LEM 10 mg
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
17
States / cities
Glendale, Arizona • Sacramento, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced Sep 26, 2026, 1:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Zolpidem Tartrate 10 mg Tablets Under Non-Fasting Conditions

NCT00833937
View directory record Official record
Conditions
Healthy
Interventions
Zolpidem 10 mg tablets, AMBIEN® 10 mg tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 26, 2026, 1:33 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder

NCT03375203
View directory record Official record
Conditions
Insomnia Disorders
Interventions
Placebo, JNJ-42847922, 5 mg, JNJ-42847922, 10 mg, JNJ-42847922, 20 mg, Zolpidem
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
24
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 26, 2026, 1:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect Of Treatment With Oral Zolpidem On Polysomnography And Actigraphy Measures In Healthy Volunteers

NCT00716521
View directory record Official record
Conditions
Methodology Study
Interventions
placebo, zolpidem
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 23, 2009 · Synced Sep 26, 2026, 1:33 PM EDT
Completed Phase 2 Interventional Results available

An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia

NCT00784875
View directory record Official record
Conditions
Primary Insomnia, Secondary Insomnia
Interventions
LY2624803, Placebo, zolpidem
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
49
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Sep 26, 2026, 1:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Zolpidem Tartrate Under Fed Conditions

NCT00602719
View directory record Official record
Conditions
Insomnia
Interventions
Zolpidem
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 26, 2026, 1:33 PM EDT
Completed Phase 2 Interventional Results available

Differential Effects of Zolpidem Versus Ramelteon in Burned Children

NCT00539110
View directory record Official record
Conditions
Sleep, Burns
Interventions
zolipidem, ramelteon
Drug
Lead sponsor
Shriners Hospitals for Children
Other
Eligibility
3 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Sep 26, 2026, 1:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Memory Consolidation in Pharmacologically Enhanced Naps

NCT00777829
View directory record Official record
Conditions
Sleep
Interventions
zolpidem, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 39 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Sep 26, 2026, 1:33 PM EDT
Completed Phase 4 Interventional Results available

Reducing Suicidal Ideation Through Insomnia Treatment

NCT01689909
View directory record Official record
Conditions
Insomnia, Depression, Suicidal Ideation
Interventions
Zolpidem-CR, Placebo
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
4
States / cities
Augusta, Georgia • Durham, North Carolina • Wake Forest, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Sep 26, 2026, 1:33 PM EDT
Active, not recruiting Not applicable Interventional

The Study in Outpatient Medicine Using Nudges to Improve Sleep

NCT06640023
View directory record Official record
Conditions
Inappropriate Prescribing
Interventions
Z-drug Default Quantity, Redirection + Accountable Justification
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 26, 2026, 1:33 PM EDT
Completed Phase 2 Interventional Results available

Xyrem(Sodium Oxybate) and Ambien(Zolpidem Tartrate) in the Treatment of Chronic Insomnia.

NCT00383643
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders
Interventions
zolpidem tartrate, sodium oxybate, Matching Placebos
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Sep 26, 2026, 1:33 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Chronic Hypnotic Use 2

NCT02456532
View directory record Official record
Conditions
Chronic Insomnia
Interventions
placebo, Zolpidem CR, Eszopiclone
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Sep 26, 2026, 1:33 PM EDT
Completed Phase 1Phase 2 Interventional

Single Dose Pharmacokinetic and Pharmacodynamic Evaluation of Three Different Doses of Zolpidem in Children

NCT00494468
View directory record Official record
Conditions
Insomnia, Sleep Disorder
Interventions
Zolpidem
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
2 Years to 18 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
11
States / cities
Little Rock, Arkansas • La Jolla, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2007 · Synced Sep 26, 2026, 1:33 PM EDT
Completed Phase 3 Interventional Results available

Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)

NCT02783729
View directory record Official record
Conditions
Insomnia
Interventions
Lemborexant, Lemborexant-matched placebo, Zolpidem tartrate, Zolpidem-matched placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
55 Years and older
Enrollment
1,006 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
60
States / cities
Jasper, Alabama • Glendale, Arizona • Little Rock, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 26, 2026, 1:33 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder

NCT02839200
View directory record Official record
Conditions
Insomnia Disorder
Interventions
ACT-541468 5 mg, ACT-541468 10 mg, ACT-541468 25 mg, Zolpidem, Placebo 1, Placebo 2
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 64 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
15
States / cities
Santa Monica, California • Upland, California • Brandon, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2020 · Synced Sep 26, 2026, 1:33 PM EDT
Completed Not applicable Interventional

Venlafaxine With or Without Zolpidem in Treating Hot Flashes and Associated Sleep Disorders in Women With Breast Cancer OR at High Risk for Developing Breast Cancer

NCT00084669
View directory record Official record
Conditions
Breast Cancer, Hot Flashes, Sleep Disorders
Interventions
venlafaxine, zolpidem tartrate, management of therapy complications
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2010 · Synced Sep 26, 2026, 1:33 PM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Imaging the Effects of Zolpidem and Alprazolam in Healthy Volunteers at 3T

NCT01747590
View directory record Official record
Conditions
Psychotropic Drugs Effects
Interventions
Zolpidem, Alprazolam, Caffeine, Placebo
Drug · Other
Lead sponsor
Mclean Hospital
Other
Eligibility
21 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Sep 26, 2026, 1:33 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

NCT04278404
View directory record Official record
Conditions
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Duke University
Other
Eligibility
0 Years to 20 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 26, 2026, 1:33 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Sedative-Anxiolytic Effects on Simulated Driving Performance

NCT03297944
View directory record Official record
Conditions
Psychomotor Impairment
Interventions
Alprazolam 2mg (2ALP/PLC), Alprazolam 1mg (1ALP/PLC), Alprazolam 0.5mg (0.5ALP/PLC), Zolpidem 10mg (ZOL/PLC), Placebo (PLC/PLC), Alprazolam 1mg (PLC/ALC)
Drug
Lead sponsor
Marion Coe
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Sep 26, 2026, 1:33 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Two Contrasting Interventions for Sleep Management

NCT01804036
View directory record Official record
Conditions
Primary Insomnia, Secondary Insomnia
Interventions
Zolpidem, Mind-Body Bridging
Drug · Behavioral
Lead sponsor
University of Utah
Other
Eligibility
17 Years to 40 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Colorado Springs, Colorado • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Sep 26, 2026, 1:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem

NCT05106153
View directory record Official record
Conditions
Healthy Non-dependent, Recreational Sedative Users, Abuse Potential
Interventions
Suvorexant, Zolpidem, Seltorexant, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 26, 2026, 1:33 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Characteristics of Sleep Patterns in Young Adults With and Without Insomnia

NCT00177216
View directory record Official record
Conditions
Sleep Disorders
Interventions
Zolpidem, Escitalopram, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
20 Years to 50 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Sep 26, 2026, 1:33 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Hypnotic Medications and Memory: Effect of Drug Exposure During the Night

NCT01159652
View directory record Official record
Conditions
Sleep, Memory
Interventions
zaleplon, zolpidem extended release, bedtime placebo, middle of the night placebo
Drug
Lead sponsor
St. Luke's Hospital, Chesterfield, Missouri
Other
Eligibility
18 Years to 50 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 25, 2014 · Synced Sep 26, 2026, 1:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of a Hypocretin/Orexin Antagonist on Neurocognitive Performance

NCT01243060
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Almorexant, Zolpidem 10mg, Placebo
Drug
Lead sponsor
Northern California Institute of Research and Education
Other
Eligibility
19 Years to 39 Years
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2014 · Synced Sep 26, 2026, 1:33 PM EDT